Canada
Puerto Rico
USA
Belgium
France
UK
IndiaThe industry isn’t short on ambition. It isn’t short on investment. And it certainly isn’t short on AI.
What it is short on is organizational decisiveness—the will to move AI from recommendation to action.
The AWS Life Sciences Symposium 2026 set the tone for where the industry is headed—and raised the bar in the process. Over 1,400 leaders from pharma, biotech, CROs, and MedTech gathered in New York for a day that truly reflected its position as the sector’s premier AI gathering. The energy was unmistakable. But what surprised me wasn’t the ambition in the room. It was honesty.
For the first time, I heard executives from some of the largest pharmaceutical companies say—clearly, on stage—that their AI problem is not a technology problem. The models work. The cloud scales. The data exists. And yet, outcomes remain stubbornly unchanged. That admission, more than any demo or keynote, was the defining moment of the symposium.
These are the AI adoption challenges in life sciences that the symposium confronted head-on—not model limitations, but organizational ones.
The industry’s bottleneck is no longer AI. It’s how organizations make decisions.
The POC Trap
A pattern surfaced repeatedly across sessions and conversations.
Organizations identify high-value problems. They build models. They run successful pilots. And then—nothing changes. The model remains in a sandbox. The decision it was meant to inform continues to be made the same way it always has.
Merck—one of the world’s largest pharmaceutical companies—was candid about this in clinical operations. Site selection for clinical trials, one of the most consequential and expensive decisions in drug development, is still largely spreadsheet-driven and opaque at most organizations. The AI recommendations exist—functioning as AI-driven decision support systems—but the decision process hasn’t been redesigned around them. So, the insight never becomes action.
The industry has an abundance of AI pilots and a shortage of AI-driven decision making. That is the real problem—and the symposium named it directly.
Data is Available. Decision-Ready Data is Not
One insight captured the real scale of the challenge: organizations often see up to a 10x drop from data coverage to analytically usable data. Data availability is not the problem—the data exists. The challenge is making it accessible, usable, and capable of driving actionable insights at the point of decision. Organizations routinely discover—when it counts—that their data can’t support the decision at hand. Not because it isn’t there, but because it hasn’t been structured, connected, or trusted enough to act on.
Platforms like Datavant Connect and AWS Clean Rooms—privacy-preserving tools that allow organizations to link and analyze patient data across institutions without moving the underlying data—are helping close this gap by making existing data accessible and insight-ready across organizational boundaries. But technology alone doesn’t complete the work. Organizations need to measure data usability, not just data availability, and treat the gap between the two as a clinical and commercial risk.
When AI Recommends—But No One Decides
The most actionable insight came from Novartis—a global pharmaceutical company that has built decision accountability into the core of its AI operating model. Their approach is straightforward but structurally different from most:
Fewer decision-makers
Faster decision cycles—measured in days, not weeks
Explicit ownership
Full traceability to systems of record
This changes behavior. When decisions are traceable, when teams can see what data informed them, what the model recommended, and what outcome followed—AI-driven decision intelligence stops being an abstract input. It becomes part of an accountable system.
Contrast that with the more common pattern: AI recommendations enter discussions, circulate briefly, and disappear—leaving organizations believing they are “using AI” while decisions remain unchanged.
Lilly was repeatedly cited across sessions as a benchmark—not for building better models, but for embedding AI into end-to-end decision making at scale rather than confining it to siloed pilots.
The message from both examples is the same: AI doesn’t create accountability. The organization must.
You cannot automate a decision that no one owns. You can only automate the illusion of one.
The Operating Model is the Work
The next phase of AI in life sciences isn’t a technology investment. It’s an operating model investment—and the symposium made this structurally clear.
The most important architectural signal: the industry is moving from standalone AI models to agents, and from agents to orchestrated agent ecosystems. Amazon’s Bio Discovery Agent and Bedrock platform—governed infrastructure for deploying AI agents across the drug lifecycle, from target identification through commercialization—represent serious capability. The emerging model is one where organizations assemble ecosystems of internal and vendor-supplied agents, governed through a semantic hub that enforces domain context, business rules, trust, compliance, and explainability. As one session put it: be your own orchestrator.
But infrastructure only delivers value if the organization is ready to receive it. The companies winning with AI have done the difficult, often overlooked work:
Reduced decision layers
Redesigned workflows around AI inputs
Established clear accountability
Built continuous feedback loops from execution back to planning
What This Means in Practice
Pharma clients no longer need vendors who build AI. They need partners who help them operationalize decisions at scale.
At Innova Solutions, this mirrors exactly the conversations we’re having with clients. The pharma organizations that come to us frustrated aren’t frustrated with AI. They’re frustrated that AI hasn’t changed how decisions get made. Across our work, a consistent pattern emerges: the bottleneck is not model performance, it is decision readiness.
That’s where the focus needs to move:
- Stop scaling POCs—tie AI initiatives to specific decisions with clear ownership and execution paths
- Invest in data usability, not just data access—make data accessible, structured, and insight-ready before decisions demand it
- Build agent ecosystems, not monoliths—combine internal and vendor agents, governed through semantic layers not hard-coded integrations
- Redesign operating models—alongside technology, fewer decision layers, faster feedback loops, explicit accountability
- Make trust and explainability foundational—regulatory readiness and transparent decision logic are features, not constraints
AI success in life sciences is no longer about better algorithms. It is about better data foundations, accountable decisions, and operational execution. The organizations that win will treat AI as infrastructure—not innovation theater—embed intelligence into how work gets done, and measure success by patient impact, not model accuracy.
The symposium confirmed what we’ve been telling clients: the technology is ready. The question is whether the organization is.
Take the first step and schedule a call with us today!
Key Contributors: Divya Gupta, Deputy Manager – Content/ Research & Sales Enablement
